Table 1 Participant characteristics.
From: De novo electrocardiographic abnormalities in persons living with HIV
N = 667 | |
|---|---|
Age at baseline (SD) | 50.5 (10.7) |
Male, n (%) | 570 (85) |
Smoking, n (%) | |
Never smoker | 237 (36) |
Current smoker | 173 (26) |
Former smoker | 244 (37) |
Hypertension, n (%) | 284 (43) |
Diabetes, n (%) | 21 (3.1) |
CD4 nadir < 200 cells/µL, n (%) | 271 (41) |
History of AIDS, n (%) | 110 (16) |
Protease inhibitor at baseline, n (%) | 191 (29) |
Protease inhibitor at follow-up, n (%) | 175 (26) |
Darunavir at baseline, n (%) | 111 (17) |
Darunavir at follow-up, n (%) | 101 (15) |
Atazanavir at baseline, n (%) | 74 (11) |
Atazanavir at follow-up, n (%) | 69 (10) |
Rilpivirine at baseline, n (%) | 24 (3.6) |
Rilpivirine at follow-up, n (%) | 30 (4.5) |
Efavirenz at baseline, n (%) | 210 (31) |
Efavirenz at follow-up, n (%) | 178 (27) |
Methadone uses, n (%) | 12 (1.8) |
